S1:E1 Full Circle
February 7, 2025
Get to know The Therapeutic Innovations group; who we are, where we came from, and what we’re hoping to achieve. We will go into multiple biologic therapeutic platforms, and how the evolution of the monoclonal antibody is being mirrored by those of next-generation therapeutics. And finally, how older platforms are gradually coming back as new therapies are hitting bumps in the road of development.
doi.org/10.1186/s12929-019-0592-z
S1:E2 So Apparently IPSCs Are Magic; Anyone See the Instruction Manual?
March 2025
For our second episode of Drug Discovery Diaries, the crew dives into IPSC based Drug Therapies: what makes them magical (maybe?) and what makes them challenging. We discuss personal experiences in the field and highlight where the field has been and where is it going.
S1:E3 Multi-Specific Antibodies-What Will the Evil Protein Engineering Geniuses Think of Next!
April 2025
The team discusses multi-specific therapeutic antibodies. Included in the discussion is: What has been approved by the FDA? What are the different types of formats in use? What are the challenges associated the the design and production of multi-specifics? As a bonus, the team dives into the recently revised FDA guidance on the use of animal models in therapeutic antibody drug development.
May 2025
The team discusses how the tumor microenvironment (or as Mike describes it: "The Malignancy Man Cave") creates challenges for cancer therapies. And as always, we get some updates on the team's life away from Science!
July 2025
In this episode, the team invites our first guest! Our friend and former colleague Ohad Manor joins us to discuss Artificial Intelligence (AI) and its role in Science, Health, and Drug Discovery.
S1:E6 Licensed to Kill: Inside the High-Stakes World of Antibody-Drug Conjugates
October 2025
In this episode the team discusses antibody drug conjugates (ADCs): Their benefits, drawbacks, and place in the overall repertoire of available therapies.
S1:E7 The Science of Shrinkage: A Therapeutic Discussion
Jan 10th, 2026
The Team discusses GLP-1 agonist therapies currently being used to treat diabetes and obesity, as well as for general weight loss. The discussion dives into what therapies are out there, the current data on efficacy, side effects (good and bad) and emerging information
S2:E1 The Swiss Army Cell: Multi-tooling CARs for Solid Tumors.
May 13, 2026
In this Episode we have a special guest (and old friend and colleague), Mark Wallet join us to discuss new approaches to improve Cell Therapies to Solid Tumors
S2:E2 What’s the Vector, Victor.
July 14, 2026
Mike talks with distinguished guest, Brian Tomkiwicz who is a VP at SK Pharmteco, leading their viral vector manufacturing group. We cover AAV, LVV and AdV, how they are applied, advantages, disadvantages,the past and future. We have switched toa video media platform for this episode and welcome comments on the switch.
Also on YouTube: https://youtu.be/pPGZSjaJ2II?si=gi37Sgy410VfoDcF
August, 4 2026
In this episode, Mike and Hillary are joined by an old colleague, Andrew Devaney, who started as a coop and became an integral part of the protein engineering team. Andrew talks about his experiences as a young scientist, the factors that led to his career path and his perspective on the future of drug discovery.
Also on YouTube: https://youtu.be/pPGZSjaJ2II?si=gi37Sgy410VfoDcF
August, 24 2026
In this episode, Mike and Hillary have the pleasure of hosting our largest guest ever, John Lee, PhD who is an executive at SK Pharmteco to discuss the state of cell therapy, in particular, CAR-T cell therapy.
Also on YouTube: https://youtu.be/pPGZSjaJ2II?si=gi37Sgy410VfoDcF